(RTTNews) - Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Sell rating on Sanofi (SNYNF – Research Report), with a price target of €90.00. The company’s shares closed ...

TORINO, Italy--(BUSINESS WIRE)--Resalis Therapeutics announced today a strategic equity investment from Sanofi. The company intends to use the proceeds to accelerate the development of its lead ...

Q3 2024 Earnings Call Transcript October 25, 2024 Sanofi beats earnings expectations. Reported EPS is $1.57, expectations ...

Sanofi will keep a significant stake in the ... Lastly, we completed a licensing agreement with RadioMedix and Orano Med for ...

Sanofi (Euronext: SAN) reported 15.7% sales growth for the third quarter of 2024 reaching 13.4 billion euros ($14.2 billion), with adjusted earnings per share (EPS) rising by 12.2% to 2.86 euros, ...

Sanofi SAN1.67%increase; green up pointing triangle reported third-quarter earnings and sales that beat analysts’ expectations, boosted by earlier-than-anticipated deliveries of flu and ...

Sanofi expects a low single-digit decline in flu shot sales due to the soft vaccination rate. Sanofi reaffirms that Dupixent will deliver around 13 billion euros in 2024 sales. The company ...

PARIS (AP) — PARIS (AP) — Sanofi (SNY) on Friday reported third-quarter earnings of $3.09 billion. The company said it had net income of $1.23 per share. Earnings, adjusted for non-recurring ...

(Reuters) - French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted by an earlier-than-anticipated start of the vaccination season.